#ASCO19 Opening Session - Focus on Patients

The theme of this year's ASCO Annual meeting was

Caring For Every Patient, Learning From Every Patient

This theme was exhibited in many sessions I attended and highlighted in the Opening Session starting with Dr Bertagnolli, in her President's Address.You may read her complete speech at
https://connection.asco.org/blogs/2019-presidential-address-caring-every-patient-learning-every-patient?cid=DM1990&bid=15208062

First up @ASCOPres announcing mCODE: open source, free data standards that will allow for easier collection of EHR data....the same language for EHRs and the ability to communicate between platforms. This is big for #interoperability #ASCO19 pic.twitter.com/NhNcvBH5Bu

— Amanda Narod (@AmandaBinDC) June 1, 2019

All EHRs need to communicate with each other.
#ASCO19 ASCO President pic.twitter.com/qPVIXIWs81

— Dee Sparacio (@womenofteal) June 1, 2019

Dr Ang, a medical oncologist from Aukland, New Zealand spoke next.

Thank you Dr Ang for your presentation “Chemoboy” and for thanking patients , caregivers, researchers and those who work behind the scenes. “what is the most important thing in the world -the people “ #gyncsm #ASC019 pic.twitter.com/XOPQsk5v4A

— Dee Sparacio (@womenofteal) June 1, 2019

Having read two books Dr Atul Gawande wrote,  I was thrilled to be able to hear him in person.

You can serve a patient’s quality of life and quantity of life, #ASCO19 @Atul_Gawande

— Dee Sparacio (@womenofteal) June 1, 2019

 As I heard these next words I thought of how it matched with what I would be saying later that afternoon in the Fireside Chat with Dr Dickson.

Yes patients have goals and priorities! #gncsm #ASCO19
Less then a quarter of the time physicians don’t ask! @Atul_Gawande

— Dee Sparacio (@womenofteal) June 1, 2019

Palliative care can make a difference . @DanaFarber study. @Atul_Gawande #ASCO19 pic.twitter.com/JsbSc8dce3

— Dee Sparacio (@womenofteal) June 1, 2019

It was a privilege to speak at this year's ASCO meeting and Tweet from the meeting.
I was moved by the dedication of the over 40,000 health care providers -surgeons, oncologists, nurses, social workers, and researchers from around the globe who attended the meeting to learn how to improve cancer patient care. Thank you to each and every one of them.


Dee
Every Day is a Blessing!

Oral Abstracts at #ASCO19

The Oral Abstract session took place on Monday June 3.
I was able to listen the first three abstracts presented before I left for the airport.

You may search the abstracts available online at https://abstracts.asco.org/239/IndexView_239.html
for information on the other studies presented during that session. 
5503 NACT compared to chemoradiation in cervical cancer
5504 Recurrence rates in cervical cancer abdominal vs minimally invasive surgery
5505 Niraparib and Bev vs niraparib alone in recurrent plat sensitive OC
5506 Olaparib monotherapy vs chemo for germline BRCA plat sensitive relapsed OC
5507 CLIO study on olaparib monotherapy vs chemo in plat sensitive OC
5508 EWOC-1 Three different first line chemo regimens for vulnerable elderly women with OC


5500 Powell -  Ph 3 Paclitaxel + carbo vs Paclitaxel + ifosfamidein chem naive patientswith carincosarcomea of the uterus or ovary

.@matthewapowell Paclitaxel-carboplatin is not inferior to ifos-paclitaxel in carcinosarcomas of the #ovary and #uterus in terms of OS (and maybe superior in terms of PFS) This establishes a new standard of care! #gyncsm #ASCO19 pic.twitter.com/BwABZhNCnv

— Shannon Westin (@ShannonWestin) June 3, 2019

Dr Powell discussing carcinosarcoma and GOG 261 #gyncsm #ASCO19 pic.twitter.com/fuOw55zTB8

— Dee Sparacio (@womenofteal) June 3, 2019

5501 Antill - Duralumab in adv endometrial cancer accroding to mismatch repare status PHAEDRA Study

Durvalumab is active in MMR deficient #EndometrialCancer with 43% response rate which is quite durable! Minimal activity in MMR intact disease. #gyncsm #ASCO19 pic.twitter.com/2swdfKRIFB

— Shannon Westin (@ShannonWestin) June 3, 2019

Dr Antill reporting on Durvalumab - endometrial cancer #gyncsm #ASCO19 pic.twitter.com/YCSpEq4u3D

— Dee Sparacio (@womenofteal) June 3, 2019

5502 Konstantinopoulos  Ph2 avelumab in patients with microsatellite stable(MSS)  ,microsatellite instable (MSI) and polymerase epsilon mutated  (POLE)recurent endometrial cancer

Dr Konstantinopoulas discussed Avelumab #ASCO19 pic.twitter.com/NYCJBbsTx9

— Dee Sparacio (@womenofteal) June 3, 2019

My last post on ASCO19 will be about the Opening session.

Dee
Every Day is a Blessing!